(Q40448827)

English

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. (English)

1 reference

Europe PubMed Central

20 September 2017

1 reference

based on heuristic

inferred from title

author name string

J-L Fischel

1

1 reference

Europe PubMed Central

20 September 2017

P Formento

2

1 reference

Europe PubMed Central

20 September 2017

G Milano

3

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

20 September 2017

British Journal of Cancer

1 reference

Europe PubMed Central

20 September 2017

92

1 reference

Europe PubMed Central

20 September 2017

6

1 reference

Europe PubMed Central

20 September 2017

1063-1068

1 reference

Europe PubMed Central

20 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602428

0 references

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Targeting the epidermal growth factor receptor for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Irreversible inhibitors of the erbB family of protein tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

ZD1839 (IRESSA): a selective EGFR-TK inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Receptor tyrosine kinases as targets for anticancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

An update on epidermal growth factor receptor inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Epidermal growth factor binding induces a conformational change in the external domain of its receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

22 September 2017

Epidermal growth factor receptor expression and suramin cytotoxicity in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

15 June 2018

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

20 August 2018

[Quick method for sensitivity tests of malignant tumors against antineoplastic agents].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361947

20 August 2018

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the epidermal growth factor receptor: a clinical reality

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of the tyrosine kinase domain

1 reference

https://pubmed.ncbi.nlm.nih.gov/15756277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemoprevention of breast cancer: a model for change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602428

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6602428

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40448827&oldid=1493964479"